Hookipa Pharma (NASDAQ:HOOK) Downgraded to “Sector Perform” Rating by Royal Bank of Canada

Royal Bank of Canada downgraded shares of Hookipa Pharma (NASDAQ:HOOK) from an outperform rating to a sector perform rating in a research note published on Friday, Marketbeat reports. They currently have $2.00 price objective on the stock, down from their prior price objective of $48.00.

Separately, JMP Securities dropped their price objective on Hookipa Pharma from $24.00 to $7.00 and set a “market outperform” rating for the company in a report on Thursday, November 21st.

Hookipa Pharma Trading Down 5.6 %

NASDAQ HOOK opened at $2.02 on Friday. The company has a market cap of $24.35 million, a PE ratio of -0.54 and a beta of 0.71. Hookipa Pharma has a 12 month low of $1.88 and a 12 month high of $11.30. The stock has a 50 day moving average of $3.06 and a 200-day moving average of $4.69.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in HOOK. Renaissance Technologies LLC boosted its holdings in Hookipa Pharma by 38.4% during the 2nd quarter. Renaissance Technologies LLC now owns 302,246 shares of the company’s stock worth $179,000 after acquiring an additional 83,800 shares during the last quarter. Ikarian Capital LLC bought a new stake in Hookipa Pharma in the 3rd quarter valued at about $228,000. Finally, Acadian Asset Management LLC raised its position in shares of Hookipa Pharma by 12.3% in the second quarter. Acadian Asset Management LLC now owns 991,106 shares of the company’s stock valued at $586,000 after purchasing an additional 108,844 shares during the period. 63.88% of the stock is owned by institutional investors and hedge funds.

Hookipa Pharma Company Profile

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.